Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB1 and unidentified receptors

We suggest that (+)-CBD analogues have mixed agonist/antagonist activity in the brain. Second, (−)-CBD analogues which are devoid of cannabinoid receptor affinity but which inhibit intestinal motility, suggest the existence of a non-CB1, non-CB2 receptor. Therefore, such analogues should be further developed as antidiarrheal and/or antiinflammatory drugs. We propose to study the therapeutic potential of (−)- and (+)-CBD derivatives for complex conditions such as inflammatory bowel disease and cystic fibrosis.